Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 494
Filter
1.
AJNR Am J Neuroradiol ; 43(5): 696-700, 2022 05.
Article in English | MEDLINE | ID: mdl-35450854

ABSTRACT

BACKGROUND AND PURPOSE: Noninvasive perfusion-weighted imaging with short scanning time could be advantageous in order to determine presumed penumbral regions and subsequent treatment strategy for acute ischemic stroke (AIS). Our aim was to evaluate interobserver agreement and the clinical utility of intravoxel incoherent motion MR imaging in patients with acute ischemic stroke. MATERIALS AND METHODS: We retrospectively studied 29 patients with AIS (17 men, 12 women; mean age, 75.2 [SD, 12.0 ] years; median, 77 years). Each patient underwent intravoxel incoherent motion MR imaging using a 1.5T MR imaging scanner. Diffusion-sensitizing gradients were applied sequentially in the x, y, and z directions with 6 different b-values (0, 50, 100, 150, 200, and 1000 seconds/mm2). From the intravoxel incoherent motion MR imaging data, diffusion coefficient, perfusion fraction, and pseudodiffusion coefficient maps were obtained using a 2-step fitting algorithm based on the Levenberg-Marquardt method. The presence of decreases in the intravoxel incoherent motion perfusion fraction and pseudodiffusion coefficient values compared with the contralateral normal-appearing brain was graded on a 2-point scale by 2 independent neuroradiologists. Interobserver agreement on the rating scale was evaluated using the κ statistic. Clinical characteristics of patients with a nondecreased intravoxel incoherent motion perfusion fraction and/or pseudodiffusion coefficient rated by the 2 observers were also assessed. RESULTS: Interobserver agreement was shown for the intravoxel incoherent motion perfusion fraction (κ = 0.854) and pseudodiffusion coefficient (κ = 0.789) maps, which indicated almost perfect and substantial agreement, respectively. Patients with a nondecreased intravoxel incoherent motion perfusion fraction tended to show recanalization of the occluded intracranial arteries more frequently than patients with a decreased intravoxel incoherent motion perfusion fraction. CONCLUSIONS: Intravoxel incoherent motion MR imaging could be performed in < 1 minute in addition to routine DWI. Intravoxel incoherent motion parameters noninvasively provide feasible, qualitative perfusion-related information for assessing patients with acute ischemic stroke.


Subject(s)
Ischemic Stroke , Aged , Diffusion Magnetic Resonance Imaging/methods , Female , Humans , Ischemic Stroke/diagnostic imaging , Male , Motion , Reproducibility of Results , Retrospective Studies
2.
Niger J Clin Pract ; 21(11): 1492-1494, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30417849

ABSTRACT

CONTEXT AND AIMS: Japanese cuisine is now popular worldwide, and consumption of raw fish has thus increased at sushi bars and Japanese restaurants outside Japan. Anisakiasis, also known as herring-worm disease, is caused by ingesting larval nematodes in raw seafood and is a common illness in Japan. However, due to the rising popularity of Japanese food, gastroenterologists outside Japan need to be familiar with this disease. SUBJECTS AND METHODS AND RESULTS: We treated 158 patients presenting with acute gastrointestinal manifestations caused by anisakiasis from April 1991 to April 2000. One or more nematodes were removed endoscopically within 48 h of presentation in 44% of these patients, which resulted in prompt resolution of symptoms. Major endoscopic findings were gastric ulcer accompanied by hemorrhage, erosion, redness, and edema of the gastric mucosa in areas penetrated by larvae and other areas. CONCLUSIONS: Endoscopy was valuable for the diagnosis and treatment of anisakiasis. We recommend endoscopy in suspected cases of anisakiasis. Moreover, it is desirable to combine complementary tests such as immunological tests/IgE measurement. As the popularity of Japanese cuisine increases, reports of anisakiasis are likely to be more frequent in countries other than Japan.


Subject(s)
Anisakiasis/diagnosis , Anisakis , Gastric Mucosa/pathology , Intestinal Obstruction/parasitology , Seafood/parasitology , Stomach Diseases/parasitology , Adolescent , Adult , Animals , Anisakiasis/parasitology , Edema , Female , Gastric Mucosa/parasitology , Humans , Japan , Male , Middle Aged , Stomach Diseases/pathology
5.
Eur J Gynaecol Oncol ; 37(3): 426-9, 2016.
Article in English | MEDLINE | ID: mdl-27352580

ABSTRACT

BACKGROUND: Dedifferentiated endometrioid adenocarcinoma (DEAC) of the uterus was first described by Silva et al. in 2006. The tumor has high-grade endometrial carcinoma component which abruptly emerged from low-grade areas. DEAC showed more aggressive phenotype than FIGO grade 3 endometrioid adenocarcinoma. However, there have been a few studies evaluating effectiveness of adjuvant therapy for the patients with DEC. CASE REPORT: A 41-year-old case with Stage IVB DEAC that clinically showed resistance to several regimens of chemotherapy is reported. The uterine corpus tumor with size of 120 x 100 mm, and the metastases were found in lung, liver, and pelvic lymph nodes. She underwent supra-vaginal hysterectomy, left salpingo-oophorectomy, and partial resection of ileum. Pathologically, the tumor had both well differentiated and undifferentiated carcinoma components, and it was diagnosed as DEAC. After primary surgery, the patient received four regimens of adjuvant chemotherapy, however all regimens were judged as progressive disease. Subsequently, the patient died of disease seven months after surgery. CONCLUSION: The present case of DEAC had an exceedingly poor prognosis, as was suggested in the several previous reports. The review of adjuvant therapeutic modalities revealed that there has been no effective therapy in the response-evaluable patients with DEAC. Further investigations for new strategy to treat the cases with DEAC are needed.


Subject(s)
Carcinoma, Endometrioid/pathology , Cell Dedifferentiation , Uterine Neoplasms/pathology , Adult , Carcinoma, Endometrioid/therapy , Combined Modality Therapy , Female , Humans , Uterine Neoplasms/therapy
6.
Allergy ; 71(10): 1435-43, 2016 10.
Article in English | MEDLINE | ID: mdl-27061295

ABSTRACT

BACKGROUND: Specific IgE (sIgE) is often used to predict oral food challenge (OFC) outcomes in food allergy, but interpretation of the results may vary depending on the assay method employed and the patient population tested. The aim of this study was to use two commercial assay systems to determine egg-sIgE values predictive of allergy within the most common populations treated at pediatric clinics. METHODS: In a multicenter prospective study, 433 children with suspected or confirmed egg allergy underwent oral challenge (OFC) using cooked egg (CE) and raw egg (RE) powders to diagnose either true allergy in 1-year-old (group A, n = 220) or tolerance in 2- to 6-year-old (group B, n = 213). Egg white (EW)- and ovomucoid (OM)-sIgE values were measured using the ImmunoCAP(®) sIgE (ImmunoCAP) and the IMMULITE(®) 2000 3 gAllergy(™) (3gAllergy) systems. Children were recruited from six primary care clinics and 18 hospitals in Japan. RESULTS: Receiver-operating characteristic (ROC) curve analysis yielded similar areas under the curve (AUC) for the two assays (0.7-0.8). The optimal cutoff values and the probability curves (PCs) of the sIgE by the two assays to predict CE and RE OFC outcomes were determined for both groups. Values for 3gAllergy were higher than for ImmunoCAP; however, correlation of sIgE and predicted probability calculated by PCs were strong between the two methods. CONCLUSIONS: Cutoff values and PCs for egg-sIgE established using both ImmunoCAP and 3gAllergy may be useful for predicting egg allergy in early childhood patient populations.


Subject(s)
Allergens/immunology , Egg Hypersensitivity/diagnosis , Egg Hypersensitivity/immunology , Eggs/adverse effects , Immunoassay , Immunoglobulin E/immunology , Allergens/administration & dosage , Child , Child, Preschool , Female , Humans , Immunoassay/methods , Immunoassay/standards , Infant , Male , Predictive Value of Tests , Prospective Studies , ROC Curve
8.
Br J Cancer ; 112(4): 739-44, 2015 Feb 17.
Article in English | MEDLINE | ID: mdl-25628093

ABSTRACT

BACKGROUND: High-temperature-required protein A2 (HtrA2), a protein relating with apoptosis in a caspases-dependent and non-dependent manner, has been reported to be associated with chemosensitivity in several human cancers. METHODS: Tissue microarrays made from 142 patients with high-grade serous ovarian adenocarcinoma were evaluated to assess whether HtrA2 expression was related with several clinical parameters. RESULTS: Negative HtrA2 expression was observed in 36 cases (25%) of the patients, and related with significantly lower response rates of primary chemotherapy than those with positive HtrA2 expression (56% vs 83%, P<0.01). In addition, negative HtrA2 expression was identified as an independent worse prognostic factor for progression-free survival and overall survival by multivariate analyses. Furthermore, HtrA2 downregulation modulated sensitivity to platinum in serous ovarian cancer cells in vitro. CONCLUSIONS: HtrA2 expression was a predictor for sensitivity to chemotherapy, and could be a candidate of molecular target in the treatment of high-grade serous ovarian cancers.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor , Cystadenocarcinoma, Serous/diagnosis , Cystadenocarcinoma, Serous/drug therapy , Mitochondrial Proteins/physiology , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/drug therapy , Serine Endopeptidases/physiology , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/metabolism , Cell Line, Tumor , Cystadenocarcinoma, Serous/metabolism , Cystadenocarcinoma, Serous/pathology , Disease-Free Survival , Female , High-Temperature Requirement A Serine Peptidase 2 , Humans , Middle Aged , Neoplasm Grading , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Prognosis , Treatment Outcome
10.
Br J Cancer ; 110(12): 2881-6, 2014 Jun 10.
Article in English | MEDLINE | ID: mdl-24853184

ABSTRACT

BACKGROUND: X-chromosome-linked inhibitor of apoptosis (XIAP) is one of the anti-apoptotic proteins leading to chemoresistance in several cancers. The aim of this study is to evaluate the impact of XIAP expression upon ovarian clear cell carcinoma (CCC) that has a platinum-resistant phenotype. METHODS: Tissue microarrays made from 90 CCC patients were analysed for immunohistochemical expression levels of XIAP, c-Met, p-Akt and Bcl-XL. In addition, CCC cell lines were evaluated whether XIAP silencing could modulate sensitivity to platinum agent in vitro. RESULTS: High XIAP expression was observed in 30 (33%) of 90 CCC cases, and was associated with c-Met (<0.01) and Bcl-XL (<0.01) expression. Cases with high XIAP expression had lower response rate to primary platinum-based chemotherapy (10% vs 65%, P=0.02). In stages II-IV tumours, high XIAP expression was related with worse progression-free survival (PFS, P=0.02). Furthermore, high XIAP expression was identified as an independent worse prognostic factor for PFS and overall survival. Finally, downregulation of XIAP using XIAP-specific small interfering RNA increased sensitivity to cisplatin in human cancer cells derived from CCC. CONCLUSIONS: X-chromosome-linked inhibitor of apoptosis expression was correlated with chemoresistance of primary chemotherapy, and identified as a prognostic marker for CCC. X-chromosome-linked inhibitor of apoptosis could be a candidate for new therapeutic target in CCC.


Subject(s)
Adenocarcinoma, Clear Cell/genetics , Drug Resistance, Neoplasm/genetics , Ovarian Neoplasms/genetics , X-Linked Inhibitor of Apoptosis Protein/genetics , Adenocarcinoma, Clear Cell/drug therapy , Adenocarcinoma, Clear Cell/mortality , Adult , Aged , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/genetics , Cell Line, Tumor , Cell Proliferation , Cisplatin/therapeutic use , Disease-Free Survival , Down-Regulation , Female , Humans , Middle Aged , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/mortality , Proto-Oncogene Proteins c-met/biosynthesis , RNA Interference , RNA, Small Interfering , X-Linked Inhibitor of Apoptosis Protein/biosynthesis , bcl-X Protein/biosynthesis
11.
Eur J Gynaecol Oncol ; 35(6): 738-40, 2014.
Article in English | MEDLINE | ID: mdl-25556285

ABSTRACT

BACKGROUND: Ovarian yolk sac tumor (YST) that is diagnosed during pregnancy is extremely rare. CLINICAL CASE: A 22-year-old pregnant woman diagnosed with Stage IIIc YST at 17 weeks of gestation is presented. A 20-cm multilocular cystic tumor containing solid components with massive ascites was detected. Subsequently she underwent left salpingo-oophorectomy and cytoreductive surgery for peritoneal dissemination at 18 weeks of gestation, and the tumors were diagnosed as YST. After vaginal termination at 20 weeks of gestation, she received five cycles of combination therapy with bleomycin, etoposide, and cisplatin. There was no evidence of recurrence at 85 months after primary treatment. CONCLUSION: Considering the rarity, treatment strategy for advanced-staged YST should be further investigated in international collaborative studies.


Subject(s)
Endodermal Sinus Tumor/pathology , Ovarian Neoplasms/pathology , Pregnancy Complications, Neoplastic/pathology , Adult , Combined Modality Therapy , Endodermal Sinus Tumor/therapy , Female , Humans , Neoplasm Staging , Ovarian Neoplasms/therapy , Pregnancy , Pregnancy Complications, Neoplastic/therapy
12.
Article in English | MEDLINE | ID: mdl-24111280

ABSTRACT

In order to test the hypothesis about reduction in the deformation of the ligamentum flavum due to tension inside the ligamentum flavum, nonlinear finite element (FE) analysis was employed. As a preliminary analysis of natural tissue, nonlinear FE analysis was applied to a rubber plate. Assuming that the rubber is third-order Mooney-Rivlin model, the analysis and the experimental curves overlap with each other until pierced point. The maximum major strain calculated by FE analysis was feasible to predict pierced point. To apply nonlinear FE analysis for the porcine ligamentum flavum, the Mooney-Rivlin coefficient of the porcine ligamentum flavum was identified from the tensile test data. Assuming that the sharp bar pierced the ligamentum flavum when the maximum major strain reached a constant value, the required displacement became shorter by 1.0mm by applying the initial tension.


Subject(s)
Ligamentum Flavum/pathology , Ligamentum Flavum/physiopathology , Needles/adverse effects , Animals , Finite Element Analysis , Injections, Epidural/adverse effects , Swine
13.
Br J Cancer ; 109(7): 1760-5, 2013 Oct 01.
Article in English | MEDLINE | ID: mdl-24002604

ABSTRACT

BACKGROUND: Radical hysterectomy is recommended for endometrial adenocarcinoma patients with suspected gross cervical involvement. However, the efficacy of operative procedure has not been confirmed. METHODS: The patients with endometrial adenocarcinoma who had suspected gross cervical involvement and underwent hysterectomy between 1995 and 2009 at seven institutions were retrospectively analysed (Gynecologic Oncology Trial and Investigation Consortium of North Kanto: GOTIC-005). Primary endpoint was overall survival, and secondary endpoints were progression-free survival and adverse effects. RESULTS: A total of 300 patients who underwent primary surgery were identified: 74 cases with radical hysterectomy (RH), 112 patients with modified radical hysterectomy (mRH), and 114 cases with simple hysterectomy (SH). Median age was 47 years, and median duration of follow-up was 47 months. There were no significant differences of age, performance status, body mass index, stage distribution, and adjuvant therapy among three groups. Multi-regression analysis revealed that age, grade, peritoneal cytology status, and lymph node involvement were identified as prognostic factors for OS; however, type of hysterectomy was not selected as independent prognostic factor for local recurrence-free survival, PFS, and OS. Additionally, patients treated with RH had longer operative time, higher rates of blood transfusion and severe urinary tract dysfunction. CONCLUSION: Type of hysterectomy was not identified as a prognostic factor in endometrial cancer patients with suspected gross cervical involvement. Perioperative and late adverse events were more frequent in patients treated with RH. The present study could not find any survival benefit from RH for endometrial cancer patients with suspected gross cervical involvement. Surgical treatment in these patients should be further evaluated in prospective clinical studies.


Subject(s)
Adenocarcinoma/mortality , Adenocarcinoma/surgery , Endometrial Neoplasms/surgery , Hysterectomy , Uterine Cervical Neoplasms/surgery , Body Mass Index , Cervix Uteri/surgery , Disease-Free Survival , Endometrial Neoplasms/mortality , Female , Humans , Hysterectomy/adverse effects , Middle Aged , Retrospective Studies , Survival Rate , Treatment Outcome , Uterine Cervical Neoplasms/mortality
14.
Eur J Gynaecol Oncol ; 34(2): 120-3, 2013.
Article in English | MEDLINE | ID: mdl-23781580

ABSTRACT

INTRODUCTION: Genotyping of UGTI1Al could be useful for prediction of severe toxicities for patients treated with irinotecan; however, genotype-based recommended dose (RD) has not been established. The aim of the present study was to determine the RD of irinotecan in combination with cisplatin (CPT-P) for individuals with or without UGT1A1 polymorphisms. MATERIALS AND METHODS: According to polymorphisms of UGTIAl*28, *6, and *27, RDs were determined by three-case cohort methods for patients with wild-type and heterotype, and by inter-patient dose escalation for homotype patients. Pharmacokinetic studies were also evaluated. During May 2009 and July 2011, 18 Japanese patients were enrolled; 16 patients with ovarian carcinoma, and two cases with cervical cancer. The RD of irinotecan was determined as 50 mg/m2 for the patients with wild-type, 40 mg/m2 for those with heterotype, and 30 mg/m2 for homotype UGT IAl genotype. RESULTS: Patients with homotype UGTIAl1 alleles had a significantly lower glucuronidation ratio in comparison with UGTIAI wild-type and heterotype cases. CONCLUSION: UGT1A1 genotype-based RDs of irinotecan in CPT-P therapy were determined. Further studies to investigate efficacy of the RD including response evaluation are needed to confirm the present results.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Glucuronosyltransferase/genetics , Ovarian Neoplasms/drug therapy , Adult , Aged , Camptothecin/administration & dosage , Camptothecin/analogs & derivatives , Cisplatin/administration & dosage , Female , Genotype , Humans , Irinotecan , Middle Aged , Ovarian Neoplasms/genetics
15.
Eur J Gynaecol Oncol ; 33(4): 414-8, 2012.
Article in English | MEDLINE | ID: mdl-23091901

ABSTRACT

BACKGROUND: Malignant transformation of ovarian mature cystic teratoma is rare, and occurs in approximately 1% of all cases. The most common histology arising in mature cystic teratoma is squamous cell carcinoma. Less frequently, malignant transformation is represented by an endocrine tumor. To date, only five cases of large cell neuroendocrine carcinoma (LCNC) arising in a mature cystic teratoma of the ovary have been reported. CLINICAL CASE: A 69-year-old woman presented with a 15-cm left ovarian mass, and was diagnosed with Stage IV large cell carcinoma neuroendocrine carcinoma (LCNC) arising in mature cystic teratoma (MCT) of the left ovary. The patient received adjuvant chemotherapy with paclitaxel and carboplatin, however, residual tumors increased in size. Six months after the debulking surgery she succumbed to the disease. A literature review revealed LCNC of the ovary showed excessively aggressive phenotype in malignant transformation from ovarian mature cystic teratoma. CONCLUSION: The present case of LCNC arising in MCT had an exceedingly poor prognosis, which was suggested in the previous five cases reported.


Subject(s)
Carcinoma, Large Cell/pathology , Carcinoma, Neuroendocrine/pathology , Ovarian Neoplasms/pathology , Teratoma/pathology , Aged , Carcinoma, Large Cell/therapy , Carcinoma, Neuroendocrine/therapy , Female , Humans , Ovarian Neoplasms/therapy , Teratoma/therapy
16.
Eur J Gynaecol Oncol ; 33(3): 269-73, 2012.
Article in English | MEDLINE | ID: mdl-22873097

ABSTRACT

The normal serum CA125 half-life and distribution of the normal serum nadir CA125 value in patients with epithelial ovarian carcinoma (EOC) have not been determined yet. Among patients with EOC, 41 patients met the inclusion criteria of the present study: the patients that underwent complete cytoreductive surgery and six cycles of platinum-containing chemotherapy, and who had no recurrent disease more than five years. Serum CA125 half-life (T1/2) during primary surgery and primary chemotherapy was calculated and serum nadir CA125 level was evaluated by logarithmic-transformed serum CA125. Median value of nadir CA125 was 7 U/ml (range 3-20 U/ml), and the mean ln (serum nadir CA125) was 1.96 +/- 0.45. Mean T1/2 was 10.4 days in all patients, and T1/2 value was associated with the preoperative serum levels of CA125. Predicted slope of CA125 regression curve was also influenced by the preoperative CA125 value. The present study provides fundamental information with regard to normal half-life time and normal nadir of CA125 in EOC patients.


Subject(s)
Biomarkers, Tumor/blood , CA-125 Antigen/blood , Neoplasms, Glandular and Epithelial/blood , Neoplasms, Glandular and Epithelial/therapy , Ovarian Neoplasms/blood , Ovarian Neoplasms/therapy , Adult , Aged , Analysis of Variance , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Camptothecin/administration & dosage , Camptothecin/analogs & derivatives , Carboplatin/administration & dosage , Carcinoma, Ovarian Epithelial , Cisplatin/administration & dosage , Cyclophosphamide/administration & dosage , Docetaxel , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Female , Half-Life , Humans , Irinotecan , Linear Models , Middle Aged , Neoplasms, Glandular and Epithelial/pathology , Ovarian Neoplasms/pathology , Paclitaxel/administration & dosage , Reference Values , Remission Induction , Taxoids/administration & dosage
17.
Eur J Gynaecol Oncol ; 33(6): 579-83, 2012.
Article in English | MEDLINE | ID: mdl-23327049

ABSTRACT

OBJECTIVE: To evaluate prognosis of high-grade endometrial cancers, comparing serous (SC) and clear cell (CCC) types to grade 3 endometrioid carcinoma (ECG3). METHODS: Among patients with endometrial cancer treated in two decades, medical records of patients with high-grade endometrial cancer were retrospectively investigated. RESULTS: Of 447 endometrial cancers, 107 (24%) high-grade endometrial cancers were identified, with the increasing incidence in the last decade (28% vs 19%; p = 0.026). There were 24 SC, 14 CCC and 69 ECG3. Median age was 62, 68, and 61 years, respectively, with the CCC type showing an elder age than the ECG3 type (p = 0.012). The rates of patients with Stage IIIc-IV, lymph node assessment or complete resection at primary surgery, and post-operative chemotherapy were not significantly different; however, response rate to first-line chemotherapy in patients with measurable disease was lower in SC than ECG3 (3 / 11, 27% vs 14 / 19, 74%; p = 0.037), regardless of regimens. Five-year overall survival (OS) was 40%, 71%, and 71% respectively, and five-year progression-free survival (PFS) was 25%, 71%, and 61%, respectively, showing SC with worse prognosis than ECG3 on both OS (p = 0.026) and PFS (p = 0.0028). According to the multivariate analysis, age > or = 70, Stage IIIc-IV and incomplete resection were independent prognostic factors on poor OS, whereas SC, Stage IIIc-IV and incomplete resection were on poor PFS. CONCLUSIONS: The increasing trend of high-grade endometrial cancer and different outcomes according to histological subtypes, especially poor PFS and chemotherapeutic response in SC, were suggested.


Subject(s)
Adenocarcinoma, Clear Cell/mortality , Cystadenocarcinoma, Serous/mortality , Endometrial Neoplasms/mortality , Adenocarcinoma, Clear Cell/pathology , Adenocarcinoma, Clear Cell/therapy , Adult , Aged , Aged, 80 and over , Cystadenocarcinoma, Serous/pathology , Cystadenocarcinoma, Serous/therapy , Endometrial Neoplasms/pathology , Endometrial Neoplasms/therapy , Female , Humans , Middle Aged , Neoplasm Grading , Neoplasm Staging , Prognosis
18.
Clin Exp Obstet Gynecol ; 38(2): 177-9, 2011.
Article in English | MEDLINE | ID: mdl-21793285

ABSTRACT

Measles is an acute exanthema spread by airborne infection and still occurs sporadically in Japan. Its mortality rate is estimated to be 0.1% and it has no specific therapy. Here, we present two cases of measles in pregnant women immediately preceding delivery. It is required to prevent the perinatal spread of measles when pregnant women are infected immediately preceding delivery. We measured the measles antibody titer of 1,393 pregnant women by enzyme immunoassay between 2004 and 2008. The antibody-positive rate was 87.7%, but the antibody titer tended to be low in childbearing age. Preventive treatment with measles vaccination is extremely important before pregnancy in order to prevent perinatal measles.


Subject(s)
Measles/diagnosis , Pregnancy Complications, Infectious/diagnosis , Adult , Antibodies, Viral/blood , Female , Humans , Immunoglobulins/therapeutic use , Infant, Newborn , Male , Measles/immunology , Measles virus/immunology , Pregnancy , Pregnancy Complications, Infectious/immunology
19.
J Perinatol ; 31(4): 289-92, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21448182

ABSTRACT

We report a case of severe fetal anemia associated with maternal anti-M antibody that was treated by direct injection of pooled human immunoglobulin into the fetal abdominal cavity. Four treatments at a dosage of 2 g per-kg estimated fetal body weight were performed, and no side effects were observed. A healthy baby girl was delivered transvaginally at 38 weeks, with neither exchange transfusion nor phototherapy required. Follow-up over 12 months found no indications of anemia or developmental delay in the child. This is believed to be the first report of fetal anemia in a blood-type-incompatible pregnancy being treated successfully with only direct immunoglobulin injection into the fetus. The immunoglobulin may have functioned as a neutralizing antibody causing the anemia to improve.


Subject(s)
Anemia, Hemolytic , Fetal Diseases , Immunoglobulins , Injections, Intraperitoneal , Anemia, Hemolytic/diagnosis , Anemia, Hemolytic/immunology , Anemia, Hemolytic/physiopathology , Anemia, Hemolytic/therapy , Antibodies/blood , Blood Group Incompatibility/diagnosis , Blood Group Incompatibility/immunology , Blood Group Incompatibility/physiopathology , Blood Group Incompatibility/therapy , Cordocentesis , Female , Fetal Diseases/diagnosis , Fetal Diseases/immunology , Fetal Diseases/physiopathology , Fetal Diseases/therapy , Fetal Monitoring , Fetal Therapies , Fetus/immunology , Fetus/physiopathology , Histocompatibility, Maternal-Fetal/immunology , Humans , Immunization, Passive , Immunoglobulins/administration & dosage , Immunoglobulins/adverse effects , Infant , Infant, Newborn , Pregnancy , Pregnancy Outcome , Treatment Outcome , Young Adult
20.
Phys Rev Lett ; 107(25): 256803, 2011 Dec 16.
Article in English | MEDLINE | ID: mdl-22243101

ABSTRACT

We report on the mapping of quantum-Hall edge states by quasiresonant photovoltage measurements using a near-field scanning optical microscope. We have observed fine structures near sample edges that shift inward with an increase in magnetic field in accordance with the shift of the positions of the quantum-Hall edge states. We have found a transition from the weak disorder regime where compressible-incompressble strips are visible to the strong disorder regime where fluctuations smear out incompressible strips.

SELECTION OF CITATIONS
SEARCH DETAIL
...